Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $7.9 million for Q4 2025, down 0.87% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (down 0.87% YoY), and the annual figure for FY2025 was $7.9 million, down 0.87%.
  • Other Non-Current Liabilities for Q4 2025 was $7.9 million at Apellis Pharmaceuticals, up from $3.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for APLS hit a ceiling of $345.2 million in Q4 2021 and a floor of $347000.0 in Q1 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $2.7 million (2024), compared with a mean of $64.2 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 99.55% in 2022 and later soared 939.01% in 2024.
  • Apellis Pharmaceuticals' Other Non-Current Liabilities stood at $345.2 million in 2021, then plummeted by 99.44% to $1.9 million in 2022, then increased by 19.3% to $2.3 million in 2023, then soared by 244.81% to $8.0 million in 2024, then decreased by 0.87% to $7.9 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $7.9 million (Q4 2025), $3.3 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.